April 30, 2013
Enzalutamide recommended for approval in the European Union (EU) for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy 1
Chertsey, England and San Francisco, CA; 26 April, 2013: Today, Astellas Pharma Europe Ltd., the European Headquarters of Tokyo-based Astellas Pharma Inc. (TSE:4503), and Medivation, Inc. (Nasdaq:...
April 25, 2013
April 15, 2013
TOKYO, April 15, 2013 - Astellas Pharma Inc. (“Astellas”; Tokyo: 4503) today announced that Songlin Xue, M.D., Ph.D. has been named head of Global Pharmacovigilance (GPV). Dr. Xue will be located at Astellas’ Headquarters for the Americas in Northbrook, Illinois, USA and will report to Sef Kurstjens, M.D., Ph.D., newly named Chief Medical Officer at Astellas.
...
April 10, 2013
TOKYO, April 10, 2013 - Astellas Pharma Inc. (“Astellas”; Tokyo:4503) announced today that its collaborative research project with Johns HopkinsUniversity School of Medicine (“JHU”; Baltimore) identified a novel action of quetiapine in the regulation of a cell-cycle related gene in CD-1 mice. The study results were published in Translational Psychiatry, a Nature Publishing Group...
April 8, 2013
TOKYO, April 8, 2013 - Astellas Pharma Inc. (“Astellas”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) today announced that Astellas participated in the Global Health Innovative Technology Fund (GHIT Fund), the first public-private partnership of its kind in Japan. The GHIT Fund has been established to advance the research and development of new medicines, vaccines and diagnostics to fight infectious...
April 5, 2013
TOKYO and SAN DIEGO, April 4, 2013 – Astellas Pharma Inc. (Tokyo: 4503, “Astellas”) today entered into a collaboration with Ambrx Inc. (“Ambrx”) for the discovery and development of novel antibody drug conjugates (“ADCs”).
ADCs allow for the targeted delivery of drugs to the target tissue. Ambrx creates optimized ADCs using its site-specific conjugation technology along with...
April 2, 2013
San Francisco, CA and Tokyo, Japan – April 1, 2013 – Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced that the companies have established an updated interim analysis plan for the PREVAIL trial, a global Phase 3 clinical trial evaluating XTANDI® (enzalutamide) capsules in men with metastatic castration-resistant prostate cancer (mCRPC) who have not yet received chemotherapy. The planned...
March 25, 2013
Tokyo, March 25, 2013 - Zeria Pharmaceutical Co., Ltd. (Tokyo: 4559; “Zeria”) and Astellas Pharma Inc. (Tokyo: 4503; “Astellas”) announced today that as of March 25, Zeria has obtained the marketing approval of Acofide® Tablets 100mg (nonproprietary name: acotiamide hydrochloride hydrate; “Acofide”; Zeria’s development code: “Z-338”; Astellas’s development code: “YM443”)...
March 21, 2013
Nagasaki and Tokyo, Japan, March 21, 2013 – The Nagasaki University (“Nagasaki University”; Nagasaki, Japan; President: Shigeru Katamine) and Astellas Pharma Inc. (“Astellas”;Tokyo:4503; President and CEO: Yoshihiko Hatanaka) today announced that they have signed a collaborative research agreement to discover new drugs for the treatment of neglected tropical diseases (“NTDs”) caused by dengue virus. This is the second execution of...
Tokyo, Japan, March 21, 2012 – Tokyo Institute of Technology (“Tokyo Tech”; Tokyo, Japan; President: Yoshinao Mishima) and Astellas Pharma Inc. (“Astellas”;Tokyo:4503; President and CEO: Yoshihiko Hatanaka) today announced that they have signed a joint research agreement for drug discovery research utilizing Tokyo Tech’s TSUBAME2.0 supercomputer to efficiently discover candidates for the treatment of neglected tropical diseases (“...